

FORM PTO-1449 (Modified) US Patent and Trademark Office				US DEPARTMENT OF COMMERCE		Docket No. 050623.26	Application No. 09/748,412	
INFORMATION DISCLOSURE CITATION in an Application				Applicant Wouter E. Roorda				
(Use several sheets if necessary)				Filing Date December 21, 2000		Group Art Unit 3738		
U.S. PATENT DOCUMENTS								
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name		Class	Subclass	Filing Date if Appropriate
	A1							
	A2							
FOREIGN PATENT DOCUMENTS								
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country		Class	Subclass	Translation
	B1							Yes No
	B2							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)								
C1	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> , JACC 13(2):252A (1989).							
C2	Komatsu et al., <i>Neointimal Tissue Response at Sites of Coronary Stenting in Humans, Macroscopic, Histological, and Immunohistochemical Analyses</i> , Circulation, 98:224-233 (1998).							
C3	Matsumaru et al., <i>Embolectic Materials for Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn. 8(7):555-569 (1997).							
C4	Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice</i> , Chem. Pharm. Bull. 33(6):2490-2498 (1985).							
C5	Miyazawa et al., <i>Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat</i> , J. Cardiovasc. Pharmacol. 30(2):157-162 (1997).							
C6	Ohsawa et al., <i>Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> , Am. Heart J. 136(6):1081-1087 (1998).							
C7	Shigeno, <i>Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor</i> , Chem. Abstracts 125:212307 (1996).							
EXAMINER				DATE CONSIDERED				
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								